The aim of our study was to assess the levels of depression, anxiety, and fatigue in patients diagnosed with FMF (Familial Mediterranean Fever) and to examine their associations with drug compliance, attack, and being employed or not. Patients presenting to our rheumatology outpatient clinic Tel-Hashomer Classification Criteria were included in the study. Fifty-two diagnosed patients followed up in our rheumatology outpatient clinic (35 female, 17 male), and 30 healthy control subjects whose ages and genders match consisting of the accompanists and visitors of the patients (25 female, 5 male) were included. Risk for depression and anxiety was assessed with HADS (Hospital Anxiety and Depression Scale). Depression and anxiety were observed to be significantly more common in the patients with FMF compared to the healthy controls in this study. Also, the frequency of FMF attacks was found to be associated with depression, anxiety, and fatigue and that regular use of colchicine decreased fatigue. In the light of all these results, the mood should definitely be evaluated during the routine practice in case of a chronic disease such as FMF having a younger patient population compared to other rheumatic diseases, and, if needed, psychiatric support should be received. Also, it should be explained to the patients that the regular use of colchicine would be beneficial for both the disease and fatigue. There is a need for follow-up studies with large case series in order to support the results we obtained.
Introduction
Familial Mediterranean Fever (FMF) is the most common hereditary inflammatory disease characterized by recurrent attacks of fever and serosal inflammation [1] .
It is defined by clinical criteria and is associated with mutations of the MEVF gene that are believed to lead to a gain of function in the pyrin protein and thereby to an inappropriate release of Interleukin-1b. [2] [3] [4] [5] FMF patients have recurring attacks of fever, pleuritis, peritonitis, arthritis and skin lesions. Colchicine is used for treatment. Colchicine should be used regularly in order to prevent organ injury that may occur during the course of FMF [6] .
Anxiety and depression are commonly encountered problems in chronic rheumatologic diseases. They occur in diseases such as rheumatoid arthritis, ankylosing spondylitis [7] [8] [9] . However, they are ignored during daily practice. FMF is also a chronic disease characterized by recurrent attacks and, according to a widely accepted view, stress induces FMF attacks [10] .
Patients presenting to our rheumatology outpatient clinic Tel-Hashomer Classification Criteria were included in the study. The patients were selected from FMF patients presenting to the outpatient clinic consecutively. The control group was selected from patient accompanists with no known diseases affecting the musculoskeletal system and from patient visitors and the two groups were matched regarding age and gender. The study was planned as a prospective, cross-sectional study. Patients' age, gender, body mass index (BMI), education status, disease duration, occupation, comorbidities, drugs used, and demographic data were recorded. In accordance with all the principles of Helsinki declaration, consent was obtained from the local ethics committee. Written consent was obtained from all patients.
Patients younger than 18 and older than 70 years, pregnant and lactating women, patients with orthopedic problems, patients with psychiatric disorders, those with severe systemic diseases that would prevent working (cardiovascular, respiratory, severe gastroenterological and metabolic pathology), those with another inflammatory disease were excluded from the study.
Risk for depression and anxiety was assessed with Hospital anxiety and depression scale (HADS). It has been developed for determining the risk of anxiety and depression in the patient and for measuring its level and change in severity. Validity and reliability of the scale was studied by Aydemir et al. The lowest score that the patients could obtain from both subscales is 0 and the highest score is 21. Cut-off points of the Turkish version of HADS were 10 for the anxiety subscale (HAD-A) and 7 for the depression subscale (HAD-D) [11] . Fatigue severity scale was used to assess fatigue level [12] . Significance was evaluated at levels of p<0.01 and p<0.05.
Statistical analysis

Results
Fifty-two diagnosed patients followed up in our rheumatology outpatient clinic (35 female, 17 male), and 30 healthy control subjects whose ages and genders match consisting of the accompanists and visitors of the patients (25 female, 5 male) were included.
All of the patients were taking colchicine medication. As an additional rheumatologic disease, three patients had spondiloartropathy. Of the patients, 47 (94%) used colchicine regularly. Thirty-four of them (%68) had a positive family history. The comparison of the demographic characteristics of the groups was summarized in Table- 1.
The depression, anxiety, and fatigue severity scales (FSS) of the groups were summarized in Table-2 .
Depression and anxiety levels of FMF patients, working and nonworking, are summarized in Table-3 . In Table-4, the frequency of attacks was found to be significant with anxiety and depression in the positive direction, while the negative correlation between fatigue and regular drug use was shown. 
Discussion
Depression and anxiety were observed to be significantly more common in the patients with FMF compared to the healthy controls in this study. Also, the frequency of FMF attacks was found to be associated with depression, anxiety, and fatigue and that regular use of colchicine decreased fatigue.
The studies conducted today revealed that some cytokines as well as IL-1, IL-6 and TNF alpha were associated with anxiety [13, 14] .
Even during the attack-free periods of the FMF patients, it was suggested that the levels of some cytokines such as IL-18, IL-2, IL-6, IL-12, IL-17 were high and that these elevated levels indicated subclinical inflammation [14] [15] [16] [17] [18] . The frequency of anxiety and depression were shown to be increased in some inflammatory diseases with chronic inflammation [19] .
A study demonstrated that serotonin was also effective in the pathophysiology of FMF and that SSRI therapy could be useful [20] [21] [22] .
All these changes brought on by chronic inflammation and their reflections on the clinical picture can lead to the mood changes of patients. Whether there are mood changes and fatigue or not in patients with FMF have also been an issue of concern.
In a study conducted recently by Duruoz et al [19] , depression, anxiety, and fatigue were investigated in FMF patients. Depression and anxiety scores were found to be higher in FMF patients compared to the control group. The other two studies conducted determined the prevalence of anxiety higher in FMF patients compared to the control subjects, however, no difference was detected among their depression scores [23] [24] [25] [26] .
Higher frequency of anxiety and depression was noted in FMF patients compared to healthy control subjects in the study conducted by Kucuksahin et al [27] .
In a study including adolescents and children with FMF, depression scores were determined to be higher than healthy control subjects. The present study indicated an association between the frequency of FMF-attacks and levels of anxiety and depression.
We also found the levels of anxiety and depression significantly higher in FMF patients than in healthy control subjects. There was a positive correlation between attack frequency and fatigue, anxiety, and depression. In contradistinction to our study, a negative correlation was detected between the number of attacks and fatigue in the study by Duruoz et al [19] .
The changes in the patients' gender, education status, disease severity, medication doses and variations in genetic mutations may have caused this result. The regular use of colchicine was not associated with anxiety and depression whereas we found a negative correlation between regular use of colchicine and fatigue. Unlike other studies, we divided the FMF patients into two groups, namely employed and unemployed. No difference was found between two groups in terms of depression, anxiety, and fatigue.
The limitations of our study included not involving a very high number of patients into the study, not using an overall quality of life scale, not designing the study as a cross-sectional study, not including any patients during an attack. Cross-sectional planning of our work also has its limitations.
Conclusion
The frequency of depression, anxiety, and fatigue was found to be more common in FMF patients compared to the healthy control subjects in our study. The regular use of colchicine had a negative correlation with fatigue. In the light of all these results, the mood should definitely be evaluated during the routine practice in case of a chronic disease such as FMF having a younger patient population compared to other rheumatic diseases, and, if needed, psychiatric support should be received. Also, it should be explained to the patients that the regular use of colchicine would be beneficial for both the disease and fatigue. There is a need for follow-up studies with large case series in order to support the results we obtained.
